6533b85afe1ef96bd12b89e2

RESEARCH PRODUCT

The Chemistry of the [1,2,3]Triazolo[1,5-a]pyridines: An Update

subject

description

Publisher Summary This chapter discusses the recent advancement in the chemistry of [1,2,3] triazolo[1,5-a]pyridines. It describes new discoveries in the physical properties and theoretical chemistry, focusing on synthesis of [1,2,3]triazolo[1,5-a]pyridine system, synthesis of novel aryltriazolopyridines, chiral ligands from [1,2,3]triazolo[1,5-a]pyridines, pyridylcarbene formation from triazolopyridines, ring-chain isomerization on [1,2,3]triazolo[1,5-a]pyridines, and novel pyridylcarbonylpyridines. All triazolopyridines have interesting ligand properties to form polynuclear complexes with different metal ions. X-ray single-crystal studies, magnetic, photo-magnetic, and colorimetric measurements of a series of iron(II)-3-(2-pyridyl)-triazolopyridine complexes have been characterized as new mononuclear spin-crossover compounds. The study of the thermal dependence of the variation of the magnetic moment shows how the high-spin configuration changes to low spin, which means that spin-crossover behavior is present. The chapter outlines a tetranuclear complex of copper, whose structure shows a cubane tetrameric complex of copper(II) with the haemiacetalate of 2-pyridyl-[1,2,3]triazolo[1,5-a]pyrid-7-ylmethanone and a S 4 symmetry. The magnetic behavior of the complex is typical for compounds displaying significant intramolecular antiferromagnetic coupling. The experimental magnitudes and the favorable orientation of the magnetic orbitals confirm the significant antiferromagnetic interaction operating through the single alkoxo bridge. The [1,2,3]triazolo[1,5-a]pyridines are not used as pharmaceutical compounds, but the chapter discusses the preliminary studies of the pharmacological interest of some triazolopyridines, such as synthesis and evaluation of 7-arylhydroxymethyltriazolopyridines as potential cardiovascular agents, and biological evaluation of [1,2,3]triazolo[1,5-a]pyridines as new neural nitric oxide synthase inhibitors